A case of indolent systemic mastocytosis responding to treatment with Avapritinib

Abstract

Key Clinical Message Low dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.

Keywords

• Avapritinib
• hematology
• immunology
• oncology
• systemic mastocytosis